CL2019000690A1 - Formulación estable para la administración parenteral de tapentadol. - Google Patents
Formulación estable para la administración parenteral de tapentadol.Info
- Publication number
- CL2019000690A1 CL2019000690A1 CL2019000690A CL2019000690A CL2019000690A1 CL 2019000690 A1 CL2019000690 A1 CL 2019000690A1 CL 2019000690 A CL2019000690 A CL 2019000690A CL 2019000690 A CL2019000690 A CL 2019000690A CL 2019000690 A1 CL2019000690 A1 CL 2019000690A1
- Authority
- CL
- Chile
- Prior art keywords
- tapentadol
- composition
- parenteral administration
- stable formulation
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA ACUOSA PARA LA ADMINISTRACIÓN PARENTERAL QUE COMPRENDE TAPENTADOL O UNA SAL FISIOLÓGICAMENTE ACEPTABLE DE ESTE; CARACTERIZADA PORQUE LA CONCENTRACIÓN DE TAPENTADOL ES MAYOR QUE 8.00 MG/ML, EN FUNCIÓN DEL PESO DE LA BASE LIBRE DE TAPENTADOL Y EN FUNCIÓN DEL VOLUMEN TOTAL DE LA COMPOSICIÓN; DONDE LA COMPOSICIÓN COMPRENDE UN SISTEMA AMORTIGUADOR Y DONDE EL VALOR DE PH DE LA COMPOSICIÓN SE ENCUENTRA EN EL INTERVALO DE MAYOR QUE 3.0 A MENOR QUE 6.7. LA INVENCIÓN TAMBIÉN SE REFIERE A UN KIT QUE COMPRENDE LA COMPOSICIÓN DE CONFORMIDAD CON LA INVENCIÓN EN UN EMBALAJE. LA COMPOSICIÓN FARMACÉUTICA DE CONFORMIDAD CON LA INVENCIÓN ES PARTICULARMENTE ÚTIL PARA TRATAR EL DOLOR, ESPECIALMENTE EL DOLOR AGUDO, PREFERENTEMENTE EN PACIENTES ADULTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16190255 | 2016-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019000690A1 true CL2019000690A1 (es) | 2019-06-14 |
Family
ID=56997349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019000690A CL2019000690A1 (es) | 2016-09-23 | 2019-03-18 | Formulación estable para la administración parenteral de tapentadol. |
Country Status (16)
Country | Link |
---|---|
US (1) | US10898452B2 (es) |
EP (1) | EP3515412A1 (es) |
JP (1) | JP7160799B2 (es) |
KR (1) | KR20190057349A (es) |
CN (1) | CN109996533A (es) |
AU (1) | AU2017329964B2 (es) |
BR (1) | BR112019005439A2 (es) |
CA (1) | CA3037810A1 (es) |
CL (1) | CL2019000690A1 (es) |
CO (1) | CO2019002557A2 (es) |
EA (1) | EA201990744A1 (es) |
EC (1) | ECSP19019253A (es) |
IL (1) | IL265477A (es) |
MX (1) | MX2019003257A (es) |
PE (1) | PE20190908A1 (es) |
WO (1) | WO2018055070A1 (es) |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8334423D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
GB8334422D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
US4775678A (en) | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
AU614465B2 (en) | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
FR2751875B1 (fr) * | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
US6183758B1 (en) | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
US6211169B1 (en) | 1999-09-29 | 2001-04-03 | Aesgen, Inc. | Stable calcitriol solution for packaging into vials |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
US20050176790A1 (en) | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
JP4905616B2 (ja) | 2001-04-19 | 2012-03-28 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
FR2832063B1 (fr) | 2001-11-15 | 2004-08-27 | Aguettant Lab | Procede de production de solutions stables de substances phenoliques et les solutions en resultant |
WO2003077897A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
US20040101563A1 (en) | 2002-07-18 | 2004-05-27 | Kundu Subhas C. | Storage stable antihistaminic syrup formulations |
CN100344328C (zh) | 2002-09-13 | 2007-10-24 | 锡德克斯公司 | 以衍生环糊精稳定化的含有水性填充组合物的胶囊 |
US6888993B2 (en) | 2002-11-27 | 2005-05-03 | Corning Incorporated | Dispersion compensating optical fiber for SMF and transmission link including same |
ITMI20022748A1 (it) | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
ATE424215T1 (de) | 2003-01-08 | 2009-03-15 | Novartis Vaccines & Diagnostic | Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante |
US20040180915A1 (en) | 2003-03-14 | 2004-09-16 | Xanodyne Pharmacal, Inc. | Methadone-containing compositions for parenteral administration and method of use thereof |
JP2007538091A (ja) | 2004-05-17 | 2007-12-27 | ファーマコフォア・インコーポレイテッド | 痛みを処置または予防するための組成物および方法 |
DE602004007905T2 (de) | 2004-06-28 | 2008-05-08 | Grünenthal GmbH | Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
AU2005259478B2 (en) | 2004-07-01 | 2010-07-15 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
JP2008539269A (ja) | 2005-04-28 | 2008-11-13 | セラクエスト バイオサイエンシズ エルエルシー | 疼痛を治療するための方法および組成物 |
TWI329334B (en) | 2005-12-02 | 2010-08-21 | Chung Shan Inst Of Science | Manufacture method of electromagnetic interference layer for the plasma display panel |
WO2007127158A2 (en) | 2006-04-25 | 2007-11-08 | Croda, Inc | Modification of percutaneous absorption of topically active materials |
CN105561311B (zh) | 2006-04-28 | 2019-07-16 | 格吕伦塔尔有限公司 | 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物 |
DE602007011913D1 (de) | 2006-04-28 | 2011-02-24 | Gruenenthal Gmbh | Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol |
ES2339403T3 (es) | 2006-07-24 | 2010-05-19 | Janssen Pharmaceutica Nv | Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina. |
EP1905440A1 (de) | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
JP2008266168A (ja) | 2007-04-18 | 2008-11-06 | Teika Seiyaku Kk | 眼科用剤 |
EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
EP1992334A1 (en) | 2007-05-08 | 2008-11-19 | Docpharma NV/SA | Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation |
RS55769B1 (sr) * | 2007-11-23 | 2017-07-31 | Gruenenthal Gmbh | Kompozicije tapentadola |
EP2247283A2 (en) | 2007-12-06 | 2010-11-10 | Pain Therapeutics, Inc. | Micronized opioid compositions, formulations and dosage forms and methods of making same |
CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
CA2721014A1 (en) | 2008-04-08 | 2009-10-15 | Acino Pharma Ag | Aqueous pharmaceutical formulation |
PE20190391A1 (es) | 2008-10-30 | 2019-03-13 | Gruenenthal Chemie | Formas de dosificacion del tapentadol novedosas y potentes |
US20110268808A1 (en) | 2009-01-09 | 2011-11-03 | Panacea Biotec Ltd. | Dual-release pharmaceutical suspension |
WO2010100477A2 (en) | 2009-03-03 | 2010-09-10 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
US20100272815A1 (en) | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
WO2011016487A1 (ja) | 2009-08-05 | 2011-02-10 | ナガセ医薬品株式会社 | インジゴカルミン製剤 |
US20120245230A1 (en) | 2009-12-10 | 2012-09-27 | Tecnimede-Sociedade Tecnico- Medicinal, S.A. | Method and composition for preparing stable liquid formulations of paracetamol |
US20110190267A1 (en) | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
NZ602572A (en) | 2010-03-30 | 2014-11-28 | Phosphagenics Ltd | Transdermal delivery patch |
GB201006200D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
PL2680833T3 (pl) * | 2011-03-04 | 2016-08-31 | Gruenenthal Gmbh | Pozajelitowe podawanie tapentadolu |
EA035750B1 (ru) * | 2011-03-04 | 2020-08-05 | Грюненталь Гмбх | Водная фармацевтическая композиция тапентадола для перорального введения |
ES2654407T3 (es) | 2011-03-04 | 2018-02-13 | Grünenthal GmbH | Composición farmacéutica acuosa semisólida que contiene tapentadol |
WO2013144814A1 (en) | 2012-03-27 | 2013-10-03 | Fresenius Kabi Oncology Ltd. | Stable ready-to-use pharmaceutical composition of pemetrexed |
CN103159633B (zh) | 2012-07-06 | 2015-08-12 | 江苏恩华药业股份有限公司 | 他喷他多的制备方法及用于制备他喷他多的化合物 |
WO2014068372A1 (en) * | 2012-11-01 | 2014-05-08 | Torrent Pharmaceuticals Ltd | Pharmaceutical composition of tapentadol for parenteral administration |
EP2968132B1 (en) * | 2013-03-14 | 2017-09-13 | Fresenius Kabi Deutschland GmbH | Injectable morphine formulations |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
CN103735550B (zh) | 2013-12-25 | 2015-11-18 | 上海市闸北区中心医院 | 一种治疗慢性肾脏病心肌损伤的药物组合物及其应用 |
CN103735500B (zh) | 2014-01-28 | 2016-01-20 | 江苏华泽医药科技有限公司 | 盐酸他喷他多注射液及其制备方法 |
PL3273953T3 (pl) * | 2015-03-27 | 2019-07-31 | Grünenthal GmbH | Stabilny preparat do pozajelitowego podawania tapentadolu |
EP3585370A1 (en) * | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
-
2017
- 2017-09-22 EP EP17777835.4A patent/EP3515412A1/en active Pending
- 2017-09-22 PE PE2019000676A patent/PE20190908A1/es unknown
- 2017-09-22 AU AU2017329964A patent/AU2017329964B2/en active Active
- 2017-09-22 KR KR1020197011410A patent/KR20190057349A/ko not_active Application Discontinuation
- 2017-09-22 EA EA201990744A patent/EA201990744A1/ru unknown
- 2017-09-22 WO PCT/EP2017/073983 patent/WO2018055070A1/en active Search and Examination
- 2017-09-22 MX MX2019003257A patent/MX2019003257A/es unknown
- 2017-09-22 CN CN201780058585.4A patent/CN109996533A/zh active Pending
- 2017-09-22 BR BR112019005439A patent/BR112019005439A2/pt not_active Application Discontinuation
- 2017-09-22 CA CA3037810A patent/CA3037810A1/en not_active Abandoned
- 2017-09-22 JP JP2019515433A patent/JP7160799B2/ja active Active
- 2017-09-22 US US15/712,812 patent/US10898452B2/en active Active
-
2019
- 2019-03-18 CL CL2019000690A patent/CL2019000690A1/es unknown
- 2019-03-19 IL IL265477A patent/IL265477A/en unknown
- 2019-03-19 EC ECSENADI201919253A patent/ECSP19019253A/es unknown
- 2019-03-19 CO CONC2019/0002557A patent/CO2019002557A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3515412A1 (en) | 2019-07-31 |
BR112019005439A2 (pt) | 2019-06-18 |
US10898452B2 (en) | 2021-01-26 |
JP7160799B2 (ja) | 2022-10-25 |
AU2017329964B2 (en) | 2022-10-06 |
IL265477A (en) | 2019-05-30 |
JP2019529442A (ja) | 2019-10-17 |
AU2017329964A1 (en) | 2019-03-14 |
CN109996533A (zh) | 2019-07-09 |
CA3037810A1 (en) | 2018-03-29 |
PE20190908A1 (es) | 2019-06-26 |
WO2018055070A1 (en) | 2018-03-29 |
CO2019002557A2 (es) | 2019-05-10 |
ECSP19019253A (es) | 2019-03-29 |
EA201990744A1 (ru) | 2019-08-30 |
KR20190057349A (ko) | 2019-05-28 |
US20180085328A1 (en) | 2018-03-29 |
MX2019003257A (es) | 2019-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089673A1 (es) | Formulacion de premezcla de dexmedetomidina | |
EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
CO2017009400A2 (es) | Formulación estable para administración parenteral de tapentadol | |
BR112016016321A2 (pt) | Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica | |
FI3685847T3 (fi) | Komplementtiaktiivisuuden modulaattoreita | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
BR112019023981A2 (pt) | injeção de octreotida | |
PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
AR111229A1 (es) | Formulación acuosa de anticuerpo | |
EA201592003A1 (ru) | Микропищевые добавки для иммунитета | |
AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
CL2019000690A1 (es) | Formulación estable para la administración parenteral de tapentadol. | |
BR112019025215A2 (pt) | Solução farmacêutica aquosa, solução tampão aquosa, kit, e, métodos de continuamente preparar uma solução farmacêutica aquosa e de tratamento de doenças do sistema nervoso central | |
CL2019000753A1 (es) | Composición farmacéutica que comprende antagonista de receptor mineralocorticoide y su uso. | |
CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
CL2016000397A1 (es) | Tratamiento contra el cáncer | |
AR108676A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant | |
BR112017025527A2 (pt) | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. | |
AR104051A1 (es) | Formulación estable para administración parenteral de tapentadol | |
EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
CY1120282T1 (el) | Φαρμακευτικη συνθεση κιτρικης σιλδεναφιλης με την μορφη ενος εναιωρηματος για εκ του στοματος χρηση | |
TW200626133A (en) | Oral medication for twice-daily administration | |
PE20151597A1 (es) | Composicion farmaceutica de clorhidrato de s-ketamina |